The “Global UTI Drugs Market Research Report 2018” is the latest comprehensive analysis document assists the reader to build effective business strategies. This report provides an in-depth insight covering all important parameters including development trends, challenges, opportunities, key manufacturers and competitive analysis.
UTI Drugs Market -Highlights
UTI drugs are used for the treatment of urinary tract infection caused by bacterial or fungal infections. World Health Organization (WHO) estimates that approximately 50 % of women have UTI at some point in their lives resulting in more than $1 million hospitalizations per year.
WHO estimates the cost of UTI infections to be annually greater than $1 billion? It has further been stated that chances of boys being diagnosed with UTI is 1% while chances of girls being diagnosed with UTI is 3 to 8%.
On the other hand market constraints includes excellent efficacy of present antibiotics specially quinolones, growing drug resistance, unmet clinical needs, increasing incidence of chronic diseases etc. However, the rise of drug resistance has created the need for novel acting antibiotic.
The future of UTI treatment seems to be development of biologics with greater market development especially with respect to poorly growing African market. The loss of patents, weakening developed pipelines and poor expenditure on health in African region had further constrained the market growth.
UTI Drugs Market –Key Players
- Bayer AG
- Novartis AG
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- AstraZeneca
- Cipla Inc.
- Dr. Reddy’s Laboratories Ltd.
UTI Drugs Market -Segmentation
The Middle East and Africa UTI drugs market has been segmented into drug class which includes quinolones, aminoglycosides, β-lactam, azoles and others. Among all these drug classes quinolones have the largest market value due to their broad variety and excellent efficacy. The share of aminoglycosides have been reduced by a small margin as this drug is resistance.
Thus the current trend in UTI treatment is combined drug regimen. The market threat includes a form of substandard, counterfeit and spurious drugs have emerged. However it has to be noted that a huge unmet need exists for these drugs in the Middle East and African region.
Access Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2540
UTI Drugs Market –Regional Analysis
Depending on geographic region, UTI drugs market is segmented into following countries: UAE, Egypt, Saudi Arabia, Kuwait, Qatar and Oman; UAE is the largest market followed by Egypt. However the future market will be led by poorly developed parts of Africa due to large unmet needs.
Middle East and Africa UTI Drugs market:
The Middle East and Africa UTI drugs market has been evaluated to be growing market and is expected that the market will grow moderately in the future. The Middle East and Africa UTI drugs market is expected to grow with the CAGR of 4.35% during the forecast period. The growth will primary be led by unmet medical needs and rising incomes of the population.
Major Points form TOC for UTI Drugs Market Research Report – Forecast to 2022
1 Introduction
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
…TOC Continued
Get Excusive Discount @ https://www.marketresearchfuture.com/check-discount/2540
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
